Skip header and navigation

Refine By

32 records – page 1 of 4.

Acute emergency service in Reykjavik]

https://arctichealth.org/en/permalink/ahliterature55044
Source
Nord Med. 1993;108(3):88-9
Publication Type
Article
Date
1993
Author
G. Thorgeirsson
Author Affiliation
Medicinska avdelningen, Borgarspítalinn, Reykjavik.
Source
Nord Med. 1993;108(3):88-9
Date
1993
Language
Swedish
Publication Type
Article
Keywords
Aged
Education, Continuing
Emergency Medical Services - manpower - organization & administration
Emergency Medical Technicians - education
English Abstract
Female
Heart Arrest - therapy
Humans
Iceland
Male
Middle Aged
Abstract
The cardiac arrest survival rate has improved since the emergency ambulance service manned by specially trained paramedical personnel and doctors was introduced in Iceland. As the response time has been reduced, specific resuscitation measures can be applied sooner.
PubMed ID
8455979 View in PubMed
Less detail

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

https://arctichealth.org/en/permalink/ahliterature208934
Source
Diabetes Care. 1997 Apr;20(4):614-20
Publication Type
Article
Date
Apr-1997
Author
K. Pyorälä
T R Pedersen
J. Kjekshus
O. Faergeman
A G Olsson
G. Thorgeirsson
Author Affiliation
Department of Medicine, University of Kuopio, Finland.
Source
Diabetes Care. 1997 Apr;20(4):614-20
Date
Apr-1997
Language
English
Publication Type
Article
Keywords
Anticholesteremic Agents - therapeutic use
Arteriosclerosis - epidemiology
Blood pressure
Cholesterol - blood
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Coronary Disease - drug therapy - epidemiology - mortality
Diabetic Angiopathies - drug therapy - physiopathology
Double-Blind Method
Female
Humans
Lovastatin - analogs & derivatives - therapeutic use
Male
Middle Aged
Myocardial Infarction - epidemiology
Myocardial Revascularization - statistics & numerical data
Placebos
Prognosis
Risk factors
Scandinavia
Simvastatin
Survival Rate
Time Factors
Triglycerides - blood
Abstract
To assess in diabetic patients with coronary heart disease (CHD) the effect of cholesterol lowering with simvastatin on mortality and the risk of CHD and other atherosclerotic events.
A post hoc subgroup analysis was carried out on data from 202 diabetic patients and 4,242 nondiabetic patients with previous myocardial infarction or angina pectoris, serum total cholesterol 5.5-8.0 mmol/l, and serum triglycerides
Notes
Comment In: Diabetes Care. 1997 Sep;20(9):1495-69283807
Comment In: Diabetes Care. 1997 Apr;20(4):469-719096961
Comment In: Diabetes Care. 1999 Dec;22(12):209210587855
Erratum In: Diabetes Care 1997 Jun;20(6):1048
PubMed ID
9096989 View in PubMed
Less detail

Chronic atrial fibrillation--epidemiologic features and 14 year follow-up: a case control study.

https://arctichealth.org/en/permalink/ahliterature55573
Source
Eur Heart J. 1987 May;8(5):521-7
Publication Type
Article
Date
May-1987
Author
P T Onundarson
G. Thorgeirsson
E. Jonmundsson
N. Sigfusson
T. Hardarson
Source
Eur Heart J. 1987 May;8(5):521-7
Date
May-1987
Language
English
Publication Type
Article
Keywords
Adult
Atrial Fibrillation - diagnosis - mortality
Cerebrovascular Disorders - mortality
Cross-Sectional Studies
Female
Follow-Up Studies
Humans
Iceland
Male
Middle Aged
Risk
Abstract
In a randomly selected population of 9067 individuals, 32-64 years of age in 1967-1970, 25 (0.28%) had chronic atrial fibrillation (CAF). Eight had lone atrial fibrillation. In 1984 the cases were compared with an age- and sex-matched control group of 50 and found to have more cerebrovascular accidents (6 versus 2; P less than 0.05), congestive heart failure (9 versus 1; P less than 0.001), and valvular rheumatic heart disease (3 versus 0) or history consistent with rheumatic fever (6 versus 0; P less than 0.01). The mortality in the CAF group was 60% higher due to an excess in cardiovascular (relative risk 6.1; P less than 0.05) and cerebrovascular (relative risk 12.2; P less than 0.05) causes. The prevalence or incidence of ischaemic or hypertensive heart disease or the presence of coronary risk factors did not significantly differ in the two groups. By M-mode echocardiography the left atrial size, left ventricular enddiastolic dimension and left ventricular mass were increased in the CAF patients, while the systolic left ventricular shortening was significantly less. Thus, the prevalence of CAF is low in a randomly selected population 32-64 years of age and CAF is not strongly associated with ischaemic heart disease or hypertension. The CAF patients have an increased risk of dying prematurely particularly from cerebrovascular causes, even in the absence of valve disease.
PubMed ID
3497034 View in PubMed
Less detail

Comparison of interventional cardiology in two European countries: a nationwide Internet based registry study.

https://arctichealth.org/en/permalink/ahliterature118194
Source
Int J Cardiol. 2013 Sep 30;168(2):1237-42
Publication Type
Article
Date
Sep-30-2013
Author
T. Gudnason
G S Gudnadottir
B. Lagerqvist
K. Eyjolfsson
T. Nilsson
G. Thorgeirsson
K. Andersen
S. James
Author Affiliation
Department of Cardiology, Landspitali University Hospital of Iceland, Reykjavik, Iceland; Cardiovascular Research Institute of Landspitali and the University of Iceland, Iceland; University of Iceland, Reykjavik, Iceland. Electronic address: thorgudn@landspitali.is.
Source
Int J Cardiol. 2013 Sep 30;168(2):1237-42
Date
Sep-30-2013
Language
English
Publication Type
Article
Keywords
Aged
Cardiology - methods - standards
Coronary Angiography - methods - standards
Europe - epidemiology
Female
Humans
Iceland - epidemiology
Internet - standards
Male
Middle Aged
Percutaneous Coronary Intervention - methods - standards
Prospective Studies
Radiography, Interventional - methods - standards
Registries
Sweden - epidemiology
Treatment Outcome
Abstract
The practice of interventional cardiology differs between countries and regions. In this study we report the results of the first nation-wide long-term comparison of interventional cardiology in two countries using a common web-based registry.
The Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was used to prospectively and continuously collect background-, quality-, and outcome parameters for all coronary angiographies (CA) and percutaneous coronary interventions (PCI) performed in Iceland and Sweden during one year.
The rate of CA per million inhabitants was higher in Iceland than in Sweden. A higher proportion of patients had CA for stable angina in Iceland than in Sweden, while the opposite was true for ST elevation myocardial infarction. Left main stem stenosis was more commonly found in Iceland than in Sweden. The PCI rate was similar in the two countries as was the general success rate of PCI, achievement of complete revascularisation and the overall stent use. Drug eluting stents were more commonly used in Iceland (23% vs. 19%). The use of fractional flow reserve (0.2% vs. 10%) and the radial approach (0.6% vs. 33%) was more frequent in Sweden than in Iceland. Serious complications and death were very rare in both countries.
By prospectively comparing interventional cardiology in two countries, using a common web based registry online, we have discovered important differences in technique and indications. A discovery such as this can lead to a change in clinical practice and inspire prospective multinational randomised registry trials in unselected, real world populations.
PubMed ID
23232456 View in PubMed
Less detail

C-reactive protein in migraine sufferers similar to that of non-migraineurs: the Reykjavik Study.

https://arctichealth.org/en/permalink/ahliterature150995
Source
Cephalalgia. 2009 Dec;29(12):1301-10
Publication Type
Article
Date
Dec-2009
Author
L S Gudmundsson
T. Aspelund
A I Scher
G. Thorgeirsson
M. Johannsson
L J Launer
V. Gudnason
Author Affiliation
Department of Pharmacology and Toxicology, University of Iceland, Hagi Hofsvallagata 53, IS-107 Reykjavik, Iceland. lsg@hi.is
Source
Cephalalgia. 2009 Dec;29(12):1301-10
Date
Dec-2009
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
C-Reactive Protein - metabolism
Case-Control Studies
Female
Humans
Iceland - epidemiology
Male
Middle Aged
Migraine with Aura - blood - epidemiology
Migraine without Aura - blood - epidemiology
Multivariate Analysis
Prevalence
Risk factors
Vasculitis - blood - epidemiology
Young Adult
Abstract
C-reactive protein (CRP), a marker of inflammation, has been associated with cardiovascular disease. Risk of cardiovascular disease is increased in migraineurs with aura. Results from a clinical report, case-control and a cohort study suggest that CRP is elevated in migraineurs compared with non-migraineurs. We examined the proposed association in a case-control study nested within two large population-based studies. The relationship between migraine and CRP (high-sensitivity CRP) was studied in 5906 men and women aged 55.0 +/- 8.5 years in the Reykjavik Study and 1345 men and women aged 27.7 +/- 5.5 years from the Reykjavik Study for the Young. A modified version of the International Headache Society's criteria was used to categorize people into migraineurs (two or more symptoms) or non-migraineurs. Migraineurs with visual or sensory symptoms were further defined as having migraine with aura (MA) or without aura (MO). Multivariable-adjusted CRP levels were similar in migraineurs and non-migraineurs for men (0.83 vs. 0.79 mg/l, P = 0.44) and for women (0.87 vs. 0.87 mg/l, P = 0.90). When further stratified by migraine aura and age, no differences were found between non-migraineurs, MO and MA among men. In women, CRP levels were borderline higher in those with MO compared with non-migraineurs and those with MA (1.01 mg/l vs. 0.81 and 0.75 mg/l, P = 0.08 and P = 0.08) in age group 19-34 years, but significantly lower in age group 60-81 years (0.52 mg/l vs. 1.07 and 1.01 mg/l, P = 0.007 and P = 0.03). CRP levels were not increased among migraine sufferers compared with non-migraineurs. Older women migraineurs without aura had lower CRP values than non-migraineurs and migraineurs with aura.
Notes
Cites: Cephalalgia. 1988;8 Suppl 7:1-963048700
Cites: N Engl J Med. 2004 Apr 1;350(14):1387-9715070788
Cites: N Engl J Med. 1999 Feb 11;340(6):448-549971870
Cites: Neurology. 1999 Aug 11;53(3):537-4210449117
Cites: Neurology. 2005 Feb 22;64(4):614-2015728281
Cites: Neurology. 2005 Mar 22;64(6):1020-615781820
Cites: Neurology. 2005 May 10;64(9):1573-715883318
Cites: Neurology. 2005 May 24;64(10 Suppl 2):S9-1515911785
Cites: Lancet Neurol. 2005 Sep;4(9):533-4216109360
Cites: Headache. 2006 Feb;46(2):197-916492227
Cites: Cephalalgia. 2006 Apr;26(4):436-4416556245
Cites: JAMA. 2006 Jul 19;296(3):283-9116849661
Cites: Acta Biomed. 2006 Apr;77(1):4-916856701
Cites: Neurology. 2006 Jul 25;67(2):246-5116864816
Cites: Headache. 2000 Apr;40(4):276-8210759931
Cites: J Neurol Neurosurg Psychiatry. 2001 Mar;70(3):377-8111181862
Cites: J Cardiovasc Risk. 2002 Apr;9(2):67-7612006913
Cites: Circulation. 2003 Jan 28;107(3):443-712551869
Cites: J Clin Invest. 2003 Jun;111(12):1805-1212813013
Cites: Curr Atheroscler Rep. 2006 Sep;8(5):421-816901413
Cites: Cephalalgia. 2007 Apr;27(4):368-7117346306
Cites: Cephalalgia. 2007 Jul;27(7):843-617668468
Cites: Int J Cardiol. 2007 Oct 1;121(2):224-617137657
Cites: Cephalalgia. 2008 Jan;28(1):49-5617986270
Cites: Cephalalgia. 2008 Feb;28(2):157-6318197885
Cites: Headache. 1989 Nov;29(10):648-562693408
PubMed ID
19438929 View in PubMed
Less detail

Desensitization of inositol phosphate production after agonist stimulation of endothelial cells is not mediated by protein kinase C.

https://arctichealth.org/en/permalink/ahliterature12319
Source
Biochem Biophys Res Commun. 1989 Jun 30;161(3):1064-9
Publication Type
Article
Date
Jun-30-1989
Author
H. Halldórsson
G. Thorgeirsson
Author Affiliation
Department of Pharmacology, University of Iceland, Reykjavik.
Source
Biochem Biophys Res Commun. 1989 Jun 30;161(3):1064-9
Date
Jun-30-1989
Language
English
Publication Type
Article
Keywords
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
Cells, Cultured
Endothelium, Vascular - drug effects - metabolism
Enzyme Activation
Histamine - pharmacology
Humans
Inositol Phosphates - biosynthesis
Isoquinolines - pharmacology
Kinetics
Piperazines - pharmacology
Protein Kinase C - antagonists & inhibitors - metabolism
Research Support, Non-U.S. Gov't
Sugar Phosphates - biosynthesis
Tetradecanoylphorbol Acetate - pharmacology
Thrombin - physiology
Abstract
To investigate the possible role of protein kinase C activation in the desensitization of inositol phosphate production in endothelial cells we compared desensitization induced by agonists to that induced by the phorbol ester TPA. While histamine or thrombin induced desensitization of inositol phosphate production is homologous TPA induced desensitization is heterologous. The protein kinase C inhibitor H-7 reduced TPA desensitization but had no effect on the agonist induced desensitization. While downregulation of protein kinase C by long term (24 hr) treatment of the cells with TPA reduced the desensitization mediated by short term TPA-treatment it did not affect the agonist induced desensitization. These results suggest that desensitization of inositol phosphate production after agonist stimulation of endothelial cells is not mediated by protein kinase C.
PubMed ID
2742577 View in PubMed
Less detail

Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)

https://arctichealth.org/en/permalink/ahliterature54320
Source
Eur Heart J. 1998 Oct;19(10):1531-7
Publication Type
Article
Date
Oct-1998
Author
O. Faergeman
J. Kjekshus
T. Cook
K. Pyörälä
L. Wilhelmsen
G. Thorgeirsson
T R Pedersen
Author Affiliation
Department of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus, Denmark.
Source
Eur Heart J. 1998 Oct;19(10):1531-7
Date
Oct-1998
Language
English
Publication Type
Article
Keywords
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Anticholesteremic Agents - therapeutic use
Aspirin - therapeutic use
Calcium Channel Blockers - therapeutic use
Cause of Death
Comparative Study
Coronary Disease - mortality - therapy
Female
Finland - epidemiology
Follow-Up Studies
Humans
Iceland - epidemiology
Male
Middle Aged
Myocardial Revascularization
Prognosis
Scandinavia - epidemiology
Simvastatin - therapeutic use
Survival Rate
Warfarin - therapeutic use
Abstract
AIM: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries. METHODS AND RESULTS: The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and showed that death rates in 4444 patients with coronary heart disease were 30% lower in those treated with simvastatin to lower serum cholesterol than in those given placebo. Apart from this main result, the 4S provided detailed information on rates of death and other manifestations of coronary heart disease, as well as on use of non-lipid forms of therapy. There were substantial differences in 4S placebo group rates of mortality, coronary deaths and major coronary events between countries. Surgical and medical therapy varied importantly between countries. CONCLUSIONS: Major inter-country differences in rates of death and myocardial infarction in patients with coronary heart disease were likely to be due to a composite of differences in baseline characteristics including smoking. They occurred in a setting of very uneven exploitation of the potential for improving survival of patients with ischaemic heart disease.
Notes
Comment In: Eur Heart J. 1998 Oct;19(10):14199820981
PubMed ID
9820992 View in PubMed
Less detail

Different mechanisms of homologous and heterologous desensitization of thrombin-induced endothelial prostacyclin production.

https://arctichealth.org/en/permalink/ahliterature11964
Source
Eur J Pharmacol. 1991 Nov 13;208(3):193-8
Publication Type
Article
Date
Nov-13-1991
Author
H. Halldórsson
M K Magnússon
G. Thorgeirsson
Author Affiliation
Department of Pharmacology, University of Iceland, Reykjavik.
Source
Eur J Pharmacol. 1991 Nov 13;208(3):193-8
Date
Nov-13-1991
Language
English
Publication Type
Article
Keywords
Aluminum - pharmacology
Aluminum Compounds
Arachidonic Acid - secretion
Calcimycin - pharmacology
Cells, Cultured
Endothelium, Vascular - drug effects - metabolism
Epoprostenol - biosynthesis
Fluorides - pharmacology
Histamine - pharmacology
Humans
Inositol Phosphates - biosynthesis
Ionophores - pharmacology
Research Support, Non-U.S. Gov't
Stimulation, Chemical
Thrombin - pharmacology
Abstract
Several workers have described desensitization of endothelial prostacyclin production but conflicting evidence has been published regarding the mechanism of desensitization, whether it is homologous (agonist specific) or heterologous, and whether inactivation of cyclooxygenase is involved. The purpose of the present study was to determine the relation between the intensity of a first thrombin stimulus and the subsequent response to a repeat thrombin, histamine, ionophore A23187 or aluminium fluoride (AlF4) stimulation and to determine possible targets of desensitization. Following thrombin stimulation of confluent cultured human umbilical vein endothelial cells (HUVEC) only homologous desensitization of inositol phosphate production was observed. Both homologous and heterologous desensitization of arachidonic acid release and prostacyclin production occurred, the latter towards both histamine and the ionophore A23187. For any given dose of the first stimulant there was a much greater effect on the homologous response than on the heterologous response. These differences suggest different mechanisms. The homologous desensitization probably involves the receptor whereas the present results suggest that the target of heterologous desensitization is distal to calcium mobilization in the signal transduction pathway. The possibilities include decreased activity of phospholipase A2 or a decreased pool of accessible arachidonic acid.
PubMed ID
1769377 View in PubMed
Less detail

Effects of leisure-time physical activity and ventilatory function on risk for stroke in men: the Reykjavík Study.

https://arctichealth.org/en/permalink/ahliterature49980
Source
Ann Intern Med. 1999 Jun 15;130(12):987-90
Publication Type
Article
Date
Jun-15-1999
Author
U. Agnarsson
G. Thorgeirsson
H. Sigvaldason
N. Sigfusson
Author Affiliation
Icelandic Heart Association and the National University Hospital, Reykjavík.
Source
Ann Intern Med. 1999 Jun 15;130(12):987-90
Date
Jun-15-1999
Language
English
Publication Type
Article
Keywords
Cerebrovascular Disorders - prevention & control
Follow-Up Studies
Forced expiratory volume
Humans
Leisure Activities
Lung - physiology
Male
Middle Aged
Prospective Studies
Questionnaires
Risk factors
Spirometry
Vital Capacity
Abstract
BACKGROUND: Stroke is a major cause of illness, death, and health expenditures. Leisure-time physical activity may reduce the risk for stroke. OBJECTIVE: To examine the association of leisure-time physical activity and pulmonary function with risk for stroke. DESIGN: Prospective cohort study. SETTING: Reykjavík, Iceland. PARTICIPANTS: 4484 men 45 to 80 years of age followed for a mean (+/-SD) of 10.6 +/- 3.6 years. MEASUREMENTS: Patients underwent physical examination, blood sampling, and spirometry and completed a questionnaire about health and exercise. Computerized hospital records were used to identify strokes, and the Icelandic National Registry was used to identify deaths. RESULTS: New stroke developed in 249 men (5.6%) (hemorrhagic stroke in 44 [18%] and ischemic stroke in 205 [82%]). In a multivariable hazard analysis that controlled for known risk factors for cerebrovascular disease, leisure-time physical activity maintained after 40 years of age was associated with a reduced risk for stroke (relative risk, 0.69 [CI, 0.47 to 1.01] for total stroke and 0.62 [CI, 0.40 to 0.97] for ischemic stroke). Risk for stroke increased with diminished ventilatory function (FVC or FEV1) (relative risk, 1.9 [CI, 1.06 to 3.25] for the lowest compared with the highest quintile). CONCLUSION: Middle-aged men who participate in leisure-time physical activity and have good pulmonary function seem to have a lower risk for stroke than men who are not active or have diminished pulmonary function.
PubMed ID
10383369 View in PubMed
Less detail

Endothelial inositol phosphate generation and prostacyclin production in response to G-protein activation by AlF4-.

https://arctichealth.org/en/permalink/ahliterature12263
Source
Biochem J. 1989 Dec 15;264(3):703-11
Publication Type
Article
Date
Dec-15-1989
Author
M K Magnússon
H. Halldórsson
M. Kjeld
G. Thorgeirsson
Author Affiliation
Department of Pharmacology, University of Iceland, Reykjavik.
Source
Biochem J. 1989 Dec 15;264(3):703-11
Date
Dec-15-1989
Language
English
Publication Type
Article
Keywords
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
6-Ketoprostaglandin F1 alpha - biosynthesis
Aluminum - pharmacology
Aluminum Compounds
Arachidonic Acids - metabolism
Calcimycin - pharmacology
Calcium - physiology
Cells, Cultured
Dose-Response Relationship, Drug
Endothelium, Vascular - drug effects - metabolism
Epoprostenol - biosynthesis
Female
Fluorides
Fluorine - pharmacology
GTP-Binding Proteins - metabolism
Humans
Inositol Phosphates - metabolism
Isoquinolines - pharmacology
Kinetics
Pertussis Toxin
Piperazines - pharmacology
Pregnancy
Protein Kinase C - antagonists & inhibitors - metabolism
Research Support, Non-U.S. Gov't
Signal Transduction - drug effects
Sodium Fluoride - pharmacology
Tetradecanoylphorbol Acetate - pharmacology
Umbilical Veins
Virulence Factors, Bordetella - pharmacology
Abstract
In order to elucidate the role of guanine-nucleotide-binding proteins (G-proteins) in endothelial prostacyclin (PGI2) production, human umbilical vein endothelial cells, prelabelled with either [3H]inositol or [3H]arachidonic acid, were stimulated with the non-specific G-protein activator aluminium fluoride (AlF4-). AlF4- caused a dose- and time-dependent generation of inositol phosphates, release of arachidonic acid and production of PGI2. The curves for the three events were similar. When the cells were stimulated in low extracellular calcium (60 nM), they released [3H]arachidonic acid and produced PGI2, but depleting the intracellular Ca2+ stores by pretreatment with the Ca2+ ionophore A23187 totally inhibited both events, although the cells still responded when extracellular Ca2+ was added. The Ca2+ ionophore did not inhibit the generation of inositol phosphates in cells maintained at low extracellular Ca2+. Pertussis toxin pretreatment (14 h) altered neither inositol phosphate nor PGI2 production in response to AlF4-. To investigate the functional role of the diacylglycerol/protein kinase C arm of the phosphoinositide system, the cells were pretreated with the protein kinase C activator 12-O-tetradecanoylphorbol 13-acetate (TPA) or the protein kinase C inhibitor 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine (H7). TPA inhibited the AlF4(-)-induced inositol phosphate generation but stimulated both the release of arachidonic acid and the production of PGI2. H7 had opposite effects both on inositol phosphate generation and on PGI2 production. These results suggest that AlF4(-)-induced PGI2 production is mediated by a pertussis-toxin-insensitive G-protein which activates the phosphoinositide second messenger system. This production of PGI2 can be modulated by protein kinase C activation, both at the level of inositol phosphate generation and at the level of arachidonic acid release.
PubMed ID
2515851 View in PubMed
Less detail

32 records – page 1 of 4.